Related Experiment Videos
Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens
Abstract:
Monoclonal antibodies (MABs) reactive with human renal cell carcinoma (RCC) were generated following immunization of mice with either RCC homogenates, RCC cell lines, or fetal kidney homogenates. The characteristics of four highly reactive immunoglobulin G1 MABs, designated UMVA-RCC-A6H, UMVA-RCC-A36, UMVA-RCC-C5H and UMVA-RCC-D5D are presented. The screening process consisted of a cell binding enzyme-linked immunosorbent assay and immunohistological examination of tumor, normal, and fetal tissue sections. The MABs illustrated various degrees of antigen restriction: A6H identified an antigen common to RCC, some lung and colon carcinomas, the proximal renal tubules but no other normal tissues; A36 reacted with most human tumors, the renal tubules, and many other normal tissues; C5H reacted with nearly every human cancer but of the normal tissues, only the renal glomerulus shared this antigen; D5D was very restrictive, reacting with many although not all RCC and no other cancers or normal tissues with the exception of an occasional reactivity with a Bowman's capsule. Metastatic RCC and RCC xenografts expressed these antigens. None of the MABs participated in complement-mediated cytotoxicity. In immunoprecipitation studies with L-[methyl-3H]methionine and [3H]glucosamine-HCl metabolically labeled RCC cells, C5H was shown to be associated with an antigen of Mr 115,000.
Insights
Researchers developed four monoclonal antibodies (MABs) targeting human renal cell carcinoma (RCC). These MABs show varying antigen specificity, with potential for RCC detection and characterization.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Monoclonal antibodies (MABs) are crucial tools in cancer research.
- Identifying specific antigens for renal cell carcinoma (RCC) can improve diagnosis and treatment.
Purpose of the Study:
- To generate and characterize novel MABs reactive with human RCC.
- To evaluate the antigen specificity and potential diagnostic utility of these MABs.
Main Methods:
- Immunization of mice with RCC homogenates, cell lines, or fetal kidney.
- Screening using cell binding enzyme-linked immunosorbent assay and immunohistochemistry.
- Immunoprecipitation studies to identify associated antigens.
Main Results:
- Four MABs (UMVA-RCC-A6H, UMVA-RCC-A36, UMVA-RCC-C5H, UMVA-RCC-D5D) were generated.
- MABs displayed diverse antigen restriction patterns, with some showing high specificity for RCC.
- MAB C5H identified an antigen of Mr 115,000 in RCC cells.
Conclusions:
- Novel MABs targeting RCC antigens have been developed.
- These MABs exhibit varying degrees of specificity, suggesting potential applications in RCC diagnostics.
- Further research is needed to explore their therapeutic potential.